Evidence map›Paper›PMID 28584253›Full record

SynthesisLeukemia2018

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.

V Shah, A L Sherborne, B A Walker, D C Johnson, E M Boyle, S Ellis, D B Begum, P Z Proszek, J R Jones, C Pawlyn and 12 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Guideline
  2. Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

V ShahDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
A L SherborneDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
B A WalkerMIRT, University of Arkansas for Medical Sciences, Little Rock, AR, USA.ORCID 0000-0002-8615-6254
D C JohnsonDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0003-0887-3343
E M BoyleDepartment of Haematology, Hopital Huriez, CHRU, Lille, France.
S EllisDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
D B BegumDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
P Z ProszekDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
J R JonesDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
C PawlynDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.ORCID 0000-0002-7190-0028
S SavolaMRC Holland, Amsterdam, The Netherlands.
M W JennerDepartment of Haematology, University Hospital Southampton, Southampton, UK.
M T DraysonClinical Immunology, School of Immunity & Infection, University of Birmingham, Birmingham, UK.
R G OwenDepartment of Haematology, St James's University Hospital, Leeds, UK.
R S HoulstonDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
D A CairnsClinical Trials Research Unit, University of Leeds, Leeds, UK.ORCID 0000-0002-2338-0179
W M GregoryClinical Trials Research Unit, University of Leeds, Leeds, UK.
G CookSection of Experimental Haematology, Leeds Institute of Cancer & Pathology, University of Leeds, Leeds, UK.
F E DaviesMIRT, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
G H JacksonDepartment of Haematology, Newcastle University, Newcastle upon Tyne, UK.
G J MorganMIRT, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
M F KaiserDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.

Funding

Cancer Research UK A12136Cancer Research UK A14261Cancer Research UK A17761Medical Research Council G0100132
6 · The paper itself

Abstract

Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent genetic aberrations is required as outcomes are variable despite apparent similar staging. We assayed copy number alterations (CNA) and translocations in 1036 patients from the NCRI Myeloma XI trial and linked these to overall survival (OS) and progression-free survival. Through a meta-anlysis of these data with data from MRC Myeloma IX trial, totalling 1905 newly diagnosed MM patients (NDMM), we confirm the association of t(4;14), t(14;16), t(14;20), del(17p) and gain(1q21) with poor prognosis with hazard ratios (HRs) for OS of 1.60 (P=4.77 × 10

Indexed as

AdultAgedAged, 80 and overChromosome AberrationsChromosome DeletionClinical Trials, Phase III as TopicDisease-Free SurvivalFemaleHumansMaleMiddle AgedMultiple MyelomaNeoplasm Recurrence, LocalPrognosisProportional Hazards ModelsTranslocation, Genetic

Identifiers

PMID28584253
PMCPMC5590713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.